219
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Serum Lipoprotein(a) and High-Density Lipoprotein Cholesterol Associate with Diabetic Nephropathy: Evidence from Machine Learning Perspectives

, , , , &
Pages 1847-1858 | Received 20 Feb 2023, Accepted 10 May 2023, Published online: 22 Jun 2023

References

  • Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidn Dis. 2018;71(6):884–895. doi:10.1053/j.ajkd.2017.10.026
  • Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):3798. doi:10.3390/ijms21113798
  • Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(Suppl 1):3–15. doi:10.1111/dom.14007
  • Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Decision algorithm for prescribing SGLT2 Inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(11):1678–1688. doi:10.2215/CJN.02690320
  • Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi:10.2215/CJN.11491116
  • American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabe Care. 2019;42(Suppl 1):S124–s138. doi:10.2337/dc19-S011
  • Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabet Endocrinol. 2021;9(1):22–31. doi:10.1016/S2213-8587(20)30369-7
  • Tu C, Wang L, Wei L. The role of PKM2 in diabetic microangiopathy. Diabetes Meta Synd Obesity. 2022;15:1405–1412. doi:10.2147/DMSO.S366403
  • Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557–1567. doi:10.1056/NEJMra1806939
  • Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–e595. doi:10.1161/CIR.0000000000000677
  • Deng X, Qin S, Chen Y, et al. B-RCA revealed circulating miR-33a/b associates with serum cholesterol in type 2 diabetes patients at high risk of ASCVD. Diabetes Res Clin Pract. 2018;140:191–199. doi:10.1016/j.diabres.2018.03.024
  • Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023;44(11):972–983. doi:10.1093/eurheartj/ehac709
  • Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated Lipoprotein(a) and risk of atrial fibrillation: an observational and Mendelian randomization study. J Am Coll Cardiol. 2022;79(16):1579–1590. doi:10.1016/j.jacc.2022.02.018
  • Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabe Care. 2005;28(1):164–176.
  • Chandni R, Ramamoorthy KP. Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications. World J Diabetes. 2012;3(5):105–109. doi:10.4239/wjd.v3.i5.105
  • Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabe Care. 2001;24(12):2071–2077. doi:10.2337/diacare.24.12.2071
  • Aromolaran O, Aromolaran D, Isewon I, Oyelade J. Machine learning approach to gene essentiality prediction: a review. Brief Bioinform. 2021;22(5):bbab128.
  • Lin E, Lin CH, Lane HY. Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection. Sci Rep. 2021;11(1):10179. doi:10.1038/s41598-021-89540-6
  • Care D. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabe Care. 2020;43(Suppl 1):S14–s31. doi:10.2337/dc20-S002
  • Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29. doi:10.1056/NEJMoa1114248
  • Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001;17(6):520–525. doi:10.1093/bioinformatics/17.6.520
  • Breiman L. Random forests. Mach Learn. 2001;45(1):5–32. doi:10.1023/A:1010933404324
  • Stone MA. Cross-validatory choice and assessment of statistical predictions. J Royal Stat Soc. 1974;36(2):111–147.
  • Jamieson K, Talwalkar A. Non-stochastic best arm identification and hyperparameter optimization. Artif Intell Stat. 2016;51:240–248.
  • Li L, Jamieson K, DeSalvo G, Rostamizadeh A, Talwalkar A. Hyperband: a novel bandit-based approach to hyperparameter optimization. J Mach Learn Res. 2017;18(1):6765–6816.
  • Hermans MP, Ahn SA, Rousseau MF. The mixed benefit of low lipoprotein(a) in type 2 diabetes. Lipids Health Dis. 2017;16(1):171. doi:10.1186/s12944-017-0564-9
  • Ugovšek S, Šebeštjen M. Lipoprotein(a)-the crossroads of atherosclerosis, atherothrombosis and inflammation. Biomolecules. 2021;12(1):26. doi:10.3390/biom12010026
  • Boffa MB. Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022;349:72–81. doi:10.1016/j.atherosclerosis.2022.04.009
  • Hung CC, Tsai JC, Kuo HT, Chang JM, Hwang SJ, Chen HC. Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud. 2013;10(2–3):110–120. doi:10.1900/RDS.2013.10.110
  • Piani F, Melena I, Tommerdahl KL, et al. Sex-related differences in diabetic kidney disease: a review on the mechanisms and potential therapeutic implications. J Diabetes Complications. 2021;35(4):107841. doi:10.1016/j.jdiacomp.2020.107841
  • Greiber S, Kreusel M, Pavenstädt H, Schollmeyer P, Wanner C. Lipoprotein(a) induces glomerular superoxide anion production. Nephrol Dialysis Tran. 1997;12(7):1330–1335. doi:10.1093/ndt/12.7.1330
  • Zhao H, Zhang R, Yan X, Fan K. Superoxide dismutase nanozymes: an emerging star for anti-oxidation. J Materials Chem B. 2021;9(35):6939–6957. doi:10.1039/D1TB00720C
  • Berg K. A new serum type system in man--The Ld system. Vox Sang. 1965;10(5):513–527. doi:10.1111/j.1423-0410.1965.tb01404.x
  • Alsharidah AS. Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis. Blood Res. 2022;57(2):101–105. doi:10.5045/br.2022.2021204
  • Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171–3182. doi:10.1210/jc.2008-2534
  • Pan L, Ye Y, Wo M, et al. Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis Markers. 2018;2018:5214376. doi:10.1155/2018/5214376
  • Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46(12):2681–2691. doi:10.1194/jlr.M500249-JLR200
  • Doucet C, Mooser V, Gonbert S, et al. Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine. J Am Soc Nephrol. 2000;11(3):507–513. doi:10.1681/ASN.V113507
  • Lippi G, Salvagno GL, Montagnana M, Targher G, Franchini M, Guidi GC. No correlation between lipoprotein(a) and biochemical markers of renal function in the general population. Arch Pathol Lab Med. 2008;132(9):1436–1438. doi:10.5858/2008-132-1436-NCBLAB
  • Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabe Care. 2003;26(1):S94–98.
  • Li X, Su T, Xiao H, et al. Association of the HDL-c Level with HsCRP, IL-6, U-NAG, RBP and Cys-C in Type 2 diabetes mellitus, hypertension, and chronic kidney disease: an epidemiological survey. Diabetes Meta Synd Obesity. 2020;13:3645–3654. doi:10.2147/DMSO.S265735
  • Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114(1):171–182. doi:10.1161/CIRCRESAHA.114.300935
  • Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res. 2012;111(8):1079–1090. doi:10.1161/CIRCRESAHA.111.258673
  • Zewinger S, Drechsler C, Kleber ME, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J. 2015;36(43):3007–3016. doi:10.1093/eurheartj/ehv352